A defective gene, normally found in blood cancers, could be treated with drugs already available for cancers with similar gene defects, scientists at Queen’s University Belfast and the University of Birmingham have revealed.
Scientists at Queen’s University Belfast and the University of Birmingham have revealed that tumours normally found in blood cancers with mutations in the SF3B1 gene, are capable of responding to some existing PARP inhibitors, a type of drug used to treat cancers which carry similar mutations in the BRCA1 and BRCA2 genes. Click to read more.
On Medicine
Screening for kidney cancer in Leeds
A new University of Cambridge-led study registered at the ISRCTN registry will investigate the feasibility of developing a full kidney cancer screening clinical trial.
SciePro / stock.adobe.com
Patients taking part in a pioneering lung screening program in Leeds will now have the option to be checked for kidney cancer thanks to additional funding from Yorkshire Cancer Research.
This study, led by Professor Grant Stewart, will investigate whether an extra scan for kidney cancer can be effectively introduced to mobile lung screening programs. The study follows Professor Stewart’s 2020
Around six in 10 people with kidney cancer do not experience symptoms, and they are often only diagnosed during tests for another condition or reason. This means over a third of patients are diagnosed at a late stage when the cancer is more difficult to treat. Just six in 10 patients with kidney cancer live for 5 years after diagnosis.